Search
Filters
Clear All
  • 11
  • 16
  • 122

Phase

  • 4
  • 8
  • 19
  • 2
  • 22
  • 1
  • 89
  • 146
  • 33

Found 149 will-simon trials

A listing of will-simon medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

J
James Croop, MD, PhD
1 years - 21 years
All genders
This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells …
Learn More

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

M
Michael Ferguson, MD
1 years - 17 years
All genders
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
Learn More

Renal Tumors Classification Biology and Banking Study

S
Sandeep Batra, MD
K
Kamnesh Pradhan, MD
29 years or below
All genders
What is the purpose of this study?This research trial studies kidney tumors in younger patients. The purpose of this study is to classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to …
Learn More

A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

S
S. Hamid Sayer, MD
18 years - 81 years
All genders
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R …
Learn More

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

S
Sherif Farag, MD
All genders
Observational
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
Learn More

A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

M
Mark Tann, MD
18 years - 100 years
All genders
The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.
Learn More

A Pilot Study to assess Theragnostically Planned Liver Radiation with Functional DVH Analysis to Optimize Individualized Radiation Therapy

R
Ryan Rhome, MD
18 years - 100 years
All genders
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer.
Learn More

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

K
Kathy Miller, MD
18 years or above
All genders
Phase 3
Interventional
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work inventing breast cancer from coming back (relapsing) in patients with high risk, HER2ve breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to ahemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it …
Learn More

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

L
Lisa Landrum, MD, PhD, MS
18 years or above
Female
Phase 3
Interventional
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary,ube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount ofgen made by the body which in turn may stop the growth …
Learn More
141 - 149 of 149